• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates.原发性局灶节段性肾小球硬化中的循环通透性因子:对候选因子的综述
Biomed Res Int. 2016;2016:3765608. doi: 10.1155/2016/3765608. Epub 2016 Apr 21.
2
Update on Recurrent Focal Segmental Glomerulosclerosis in Kidney Transplantation.肾移植中复发性局灶节段性肾小球硬化的研究进展。
Nephron. 2020;144 Suppl 1:65-70. doi: 10.1159/000510748. Epub 2020 Dec 1.
3
Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.特发性肾病综合征和局灶节段性肾小球硬化症中的循环通透性因子。
Clin J Am Soc Nephrol. 2010 Nov;5(11):2115-21. doi: 10.2215/CJN.03800609. Epub 2010 Oct 21.
4
A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues.局灶节段性肾小球硬化中的一种循环通透性因子:探寻仍在继续。
Clin Kidney J. 2015 Dec;8(6):708-15. doi: 10.1093/ckj/sfv090. Epub 2015 Sep 15.
5
Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?目前的 ELISA 方法检测血清 suPAR 是否为 FSGS 的可靠诊断生物标志物?
Kidney Int. 2014 Mar;85(3):499-501. doi: 10.1038/ki.2013.549.
6
Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.血清可溶性尿激酶受体水平不能区分局灶节段性肾小球硬化与儿童肾病综合征的其他病因。
Kidney Int. 2014 Mar;85(3):649-58. doi: 10.1038/ki.2013.546. Epub 2014 Jan 15.
7
[Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis].[可溶性尿激酶受体血清水平在特发性与继发性局灶节段性肾小球硬化鉴别诊断中的价值]
Nefrologia. 2014;34(1):53-61. doi: 10.3265/Nefrologia.pre2013.Oct.12272.
8
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.采用强化血浆置换及可溶性尿激酶型纤溶酶原激活物受体介导的足细胞β3整合素激活同步监测治疗复发性原发性局灶节段性肾小球硬化症
Transplantation. 2015 Dec;99(12):2593-7. doi: 10.1097/TP.0000000000000914.
9
FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy.局灶节段性肾小球硬化症通透性因子相关肾病综合征:口服半乳糖治疗后缓解
Nephrol Dial Transplant. 2009 Sep;24(9):2938-40. doi: 10.1093/ndt/gfp278. Epub 2009 Jun 9.
10
CD80, suPAR and nephrotic syndrome in a case of NPHS2 mutation.CD80、suPAR 与 NPHS2 基因突变致肾病综合征
Nefrologia. 2013;33(5):727-31. doi: 10.3265/Nefrologia.pre2013.Jun.12085.

引用本文的文献

1
Association of soluble urokinase plasminogen activator receptor and epidermal growth factor with histopathological findings of kidney biopsy: a single-center study.可溶性尿激酶型纤溶酶原激活物受体与表皮生长因子与肾活检组织病理学结果的相关性:一项单中心研究
BMC Nephrol. 2025 Jul 25;26(1):416. doi: 10.1186/s12882-025-04351-5.
2
Collapsing Focal Segmental Glomerulosclerosis With Concurrent IgG4 Nephropathy.合并IgG4肾病的塌陷性局灶节段性肾小球硬化症
Cureus. 2025 Mar 23;17(3):e81031. doi: 10.7759/cureus.81031. eCollection 2025 Mar.
3
Impact of Therapeutic Plasma Exchange and Rituximab for Prevention of Idiopathic Focal Segmental Glomerulosclerosis Recurrence Post-Kidney Transplantation.治疗性血浆置换和利妥昔单抗对预防肾移植后特发性局灶节段性肾小球硬化复发的影响。
Transplant Direct. 2025 Feb 28;11(3):e1769. doi: 10.1097/TXD.0000000000001769. eCollection 2025 Mar.
4
Increased levels of antibodies to synaptopodin and annexin 1 in patients with primary podocytopathies.原发性足细胞病患者中突触素和膜联蛋白1抗体水平升高。
Front Nephrol. 2024 Oct 31;4:1471078. doi: 10.3389/fneph.2024.1471078. eCollection 2024.
5
Safety and efficacy of sparsentan versus irbesartan in focal segmental glomerulosclerosis and IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.在局灶节段性肾小球硬化症和 IgA 肾病中, sparsentan 与厄贝沙坦的安全性和疗效:系统评价和随机对照试验的荟萃分析。
BMC Nephrol. 2024 Sep 27;25(1):316. doi: 10.1186/s12882-024-03713-9.
6
Potential biomarkers of recurrent FSGS: a review.复发性局灶节段性肾小球硬化症的潜在生物标志物:综述。
BMC Nephrol. 2024 Aug 12;25(1):258. doi: 10.1186/s12882-024-03695-8.
7
Rare heterozygous variants in paediatric steroid resistant nephrotic syndrome - a population-based analysis of their significance.儿科激素耐药性肾病综合征中罕见的杂合性变异 - 基于人群的意义分析。
Sci Rep. 2024 Aug 10;14(1):18568. doi: 10.1038/s41598-024-68837-2.
8
A Review of Focal Segmental Glomerulosclerosis Classification With a Focus on Genetic Associations.聚焦节段性肾小球硬化分类综述:重点关注基因关联
Kidney Med. 2024 Apr 17;6(6):100826. doi: 10.1016/j.xkme.2024.100826. eCollection 2024 Jun.
9
Swollen Feet: Considering the Paradoxical Roles of Interleukins in Nephrotic Syndrome.足部肿胀:探讨白细胞介素在肾病综合征中的矛盾作用
Biomedicines. 2024 Mar 26;12(4):738. doi: 10.3390/biomedicines12040738.
10
Differentiating primary and secondary FSGS using non-invasive urine biomarkers.使用非侵入性尿液生物标志物鉴别原发性和继发性局灶节段性肾小球硬化症。
Clin Kidney J. 2023 Dec 4;17(2):sfad296. doi: 10.1093/ckj/sfad296. eCollection 2024 Feb.

本文引用的文献

1
Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis.用于检测与复发性局灶节段性肾小球硬化相关的循环足细胞毒性因子的新型无偏倚检测方法。
Am J Physiol Renal Physiol. 2016 May 15;310(10):F1148-56. doi: 10.1152/ajprenal.00349.2015. Epub 2015 Dec 30.
2
B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS.B7-1阻断不能改善复发性局灶节段性肾小球硬化所致的移植后肾病综合征。
J Am Soc Nephrol. 2016 Aug;27(8):2520-7. doi: 10.1681/ASN.2015091002. Epub 2015 Dec 23.
3
A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues.局灶节段性肾小球硬化中的一种循环通透性因子:探寻仍在继续。
Clin Kidney J. 2015 Dec;8(6):708-15. doi: 10.1093/ckj/sfv090. Epub 2015 Sep 15.
4
Soluble Urokinase Receptor and Chronic Kidney Disease.可溶性尿激酶受体与慢性肾脏病
N Engl J Med. 2015 Nov 12;373(20):1916-25. doi: 10.1056/NEJMoa1506362. Epub 2015 Nov 5.
5
Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.全长可溶性尿激酶型纤溶酶原激活物受体下调足细胞中nephrin的表达。
Sci Rep. 2015 Sep 18;5:13647. doi: 10.1038/srep13647.
6
Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.半乳糖和阿达木单抗治疗抵抗性局灶节段性肾小球硬化症患者的疗效:Font临床试验组报告
BMC Nephrol. 2015 Jul 22;16:111. doi: 10.1186/s12882-015-0094-5.
7
Renal and Hematological Effects of CLCF-1, a B-Cell-Stimulating Cytokine of the IL-6 Family.CLCF-1,一种白细胞介素 6 家族的 B 细胞刺激细胞因子,对肾脏和血液系统的影响。
J Immunol Res. 2015;2015:714964. doi: 10.1155/2015/714964. Epub 2015 Jun 4.
8
Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier.Janus激酶2/信号转导及转录激活因子3抑制剂可减弱类心肌营养素因子1和人类局灶节段性肾小球硬化血清对肾小球滤过屏障的作用。
Transl Res. 2015 Oct;166(4):384-98. doi: 10.1016/j.trsl.2015.03.002. Epub 2015 Mar 16.
9
Reassessing the Reassessment of suPAR in Glomerular Disease.重新评估肾小球疾病中可溶性尿激酶型纤溶酶原激活物受体(suPAR)的再评估
Front Med (Lausanne). 2015 Jan 14;1:59. doi: 10.3389/fmed.2014.00059. eCollection 2014.
10
Causes and pathogenesis of focal segmental glomerulosclerosis.局灶节段性肾小球硬化的病因及发病机制。
Nat Rev Nephrol. 2015 Feb;11(2):76-87. doi: 10.1038/nrneph.2014.216. Epub 2014 Dec 2.

原发性局灶节段性肾小球硬化中的循环通透性因子:对候选因子的综述

Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates.

作者信息

Königshausen Eva, Sellin Lorenz

机构信息

Department of Nephrology, University Hospital, Heinrich-Heine University, Moorenstrasse 5, 40225 Duesseldorf, Germany.

出版信息

Biomed Res Int. 2016;2016:3765608. doi: 10.1155/2016/3765608. Epub 2016 Apr 21.

DOI:10.1155/2016/3765608
PMID:27200372
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4856884/
Abstract

Primary focal segmental glomerulosclerosis (FSGS) is a major cause of the nephrotic syndrome and often leads to end-stage renal disease. This review focuses on circulating permeability factors in primary FSGS that have been implicated in the pathogenesis for a long time, partly due to the potential recurrence in renal allografts within hours after transplantation. Recently, three molecules have been proposed as a potential permeability factor by different groups: the soluble urokinase plasminogen activator receptor (suPAR), cardiotrophin-like cytokine factor-1 (CLCF-1), and CD40 antibodies. Both CLCF-1 and CD40 antibodies have not been validated by independent research groups yet. Since the identification of suPAR, different studies have questioned the validity of suPAR as a biomarker to distinguish primary FSGS from other proteinuric kidney diseases as well as suPAR's pathogenic role in podocyte damage. Researchers have suggested that cleaved molecules of suPAR have a pathogenic role in FSGS but further studies are needed to determine this role. In future studies, proposed standards for the research of the permeability factor should be carefully followed. The identification of the permeability factor in primary FSGS would be of great clinical relevance as it could influence potential individual treatment regimen.

摘要

原发性局灶节段性肾小球硬化(FSGS)是肾病综合征的主要病因,常导致终末期肾病。本综述聚焦于原发性FSGS中的循环通透性因子,长期以来它们被认为与发病机制有关,部分原因是肾移植后数小时内同种异体肾移植中可能出现复发。最近,不同研究团队提出了三种分子作为潜在的通透性因子:可溶性尿激酶型纤溶酶原激活物受体(suPAR)、心肌营养素样细胞因子-1(CLCF-1)和CD40抗体。CLCF-1和CD40抗体尚未得到独立研究团队的验证。自suPAR被发现以来,不同研究对suPAR作为区分原发性FSGS与其他蛋白尿性肾病的生物标志物的有效性以及suPAR在足细胞损伤中的致病作用提出了质疑。研究人员认为,suPAR的裂解分子在FSGS中具有致病作用,但需要进一步研究来确定这一作用。在未来的研究中,应严格遵循所提出的通透性因子研究标准。确定原发性FSGS中的通透性因子具有重要的临床意义,因为它可能影响潜在的个体化治疗方案。